|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011860,
umls-concept:C0021641,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0071097,
umls-concept:C0087111,
umls-concept:C0166418,
umls-concept:C0205360,
umls-concept:C0205390,
umls-concept:C0243192,
umls-concept:C0332307,
umls-concept:C0728938,
umls-concept:C1566435,
umls-concept:C1696465,
umls-concept:C1707455,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-5-6
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Treatment of patients with perioxisome proliferator-activated receptor-? full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-? agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-? partial agonist balaglitazone in diabetic patients on stable insulin therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones,
http://linkedlifedata.com/resource/pubmed/chemical/balaglitazone,
http://linkedlifedata.com/resource/pubmed/chemical/hemoglobin A1c protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/pioglitazone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1520-7560
|
|
pubmed:author |
pubmed-author:BALLET Trial Investigators,
pubmed-author:Beck-NielsenHenningH,
pubmed-author:ByrjalsenIngerI,
pubmed-author:ChristiansenClausC,
pubmed-author:GramJeppeJ,
pubmed-author:HansenGitteG,
pubmed-author:HenriksenKimK,
pubmed-author:KarsdalMorten AMA,
pubmed-author:PerrildHansH,
pubmed-author:QvistPerP,
pubmed-author:RiisBente JBJ,
pubmed-author:SvendsenOle LanderOL
|
|
pubmed:copyrightInfo |
Copyright © 2011 John Wiley & Sons, Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
392-401
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21328517-Aged,
pubmed-meshheading:21328517-Blood Glucose,
pubmed-meshheading:21328517-Body Composition,
pubmed-meshheading:21328517-Bone Density,
pubmed-meshheading:21328517-Diabetes Mellitus, Type 2,
pubmed-meshheading:21328517-Dose-Response Relationship, Drug,
pubmed-meshheading:21328517-Double-Blind Method,
pubmed-meshheading:21328517-Drug Therapy, Combination,
pubmed-meshheading:21328517-Female,
pubmed-meshheading:21328517-Hemoglobin A, Glycosylated,
pubmed-meshheading:21328517-Humans,
pubmed-meshheading:21328517-Hypoglycemic Agents,
pubmed-meshheading:21328517-Insulin,
pubmed-meshheading:21328517-Male,
pubmed-meshheading:21328517-Middle Aged,
pubmed-meshheading:21328517-PPAR gamma,
pubmed-meshheading:21328517-Quinazolines,
pubmed-meshheading:21328517-Thiazolidinediones,
pubmed-meshheading:21328517-Water-Electrolyte Balance,
pubmed-meshheading:21328517-Weight Gain
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Efficacy and safety of the PPAR? partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
|
|
pubmed:affiliation |
Nordic Bioscience A/S, Herlev, Denmark. kh@nordicbioscience.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
